Global COPD Pricing, Reimbursement, and Access Report 2016 - Which LABA/LAMAs Have Been Most Successful in Securing National Reimbursement and why? -
DUBLIN, August 11, 2016 /PRNewswire/
Research and Markets has announced the addition of the "Copd Pricing, Reimbursement, and Access" report to their offering.
MARKET CONTEXT
・While traditional first-line medications face generic competition, pipeline triple combinations and LABA/LAMAs will fuel modest growth in COPD
GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS
・LABA/LAMAs set to overtake ICS/LABAs in non-exacerbating COPD patients
・Longer clinical trials with clinically significant results favored by both US and EU payers
US REIMBURSEMENT
・GOLD guidelines are widely used for COPD
FIVE MAJOR EU MARKETS PRICING
・First-to-market Utibron enjoys high prices in most EU markets
FIVE MAJOR EU MARKETS PAYER INSIGHTS
・With the exception of the UK, GOLD remains the most frequently used guideline in EU Countries
ttp://www.prnewswire.com/news-releases/global-copd-pricing-reimbursement-and-access-report-2016---which-labalamas-have-been-most-successful-in-securing-national-reimbursement-and-why---research-and-markets-300312606.html
Nature Reviews Drug Discovery: "Biophysics in drug discovery: impact, challenges and opportunities"
Published online 12 August, 2016
・・・Most current studies on purified GPCRs use stabilized variants of receptors, and substantial progress in biophysical screening (SPR and target-immobilized NMR screening (TINS)) has been demonstrated by Heptares and ZoBio. ・・・
Global COPD Pricing, Reimbursement, and Access Report 2016 - Which LABA/LAMAs Have Been Most Successful in Securing National Reimbursement and why? -
DUBLIN, August 11, 2016 /PRNewswire/
Research and Markets has announced the addition of the "Copd Pricing, Reimbursement, and Access" report to their offering.
MARKET CONTEXT
・While traditional first-line medications face generic competition, pipeline triple combinations and LABA/LAMAs will fuel modest growth in COPD
GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS
・LABA/LAMAs set to overtake ICS/LABAs in non-exacerbating COPD patients
・Longer clinical trials with clinically significant results favored by both US and EU payers
US REIMBURSEMENT
・GOLD guidelines are widely used for COPD
FIVE MAJOR EU MARKETS PRICING
・First-to-market Utibron enjoys high prices in most EU markets
FIVE MAJOR EU MARKETS PAYER INSIGHTS
・With the exception of the UK, GOLD remains the most frequently used guideline in EU Countries
ttp://www.prnewswire.com/news-releases/global-copd-pricing-reimbursement-and-access-report-2016---which-labalamas-have-been-most-successful-in-securing-national-reimbursement-and-why---research-and-markets-300312606.html
Nature Reviews Drug Discovery: "Biophysics in drug discovery: impact, challenges and opportunities"
Published online 12 August, 2016
・・・Most current studies on purified GPCRs use stabilized variants of receptors, and substantial progress in biophysical screening (SPR and target-immobilized NMR screening (TINS)) has been demonstrated by Heptares and ZoBio. ・・・